3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
11
Phase 1
4
Phase 1/2
3
Phase 3
2
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Lymphoma, Non-Hodgkin
1
Lymphoma, Large B-Cell, Diffuse
1
Interventions
pembrolizumab
133
Carboplatin
132
Cisplatin
119
Paclitaxel
104
Gemcitabine
89
Specimen Handling
82
Magnetic Resonance Spectroscopy
82
Docetaxel
73
Dexamethasone
60
Cyclophosphamide
60
Pemetrexed
57
durvalumab
55
Bevacizumab
55
Capecitabine
54
Radiotherapy
51
Doxorubicin
51
Oxaliplatin
50
Fluorouracil
48
Radiation
47
Rituximab
43
Leucovorin
43
Vincristine
41
Lenalidomide
40
Etoposide
39
atezolizumab
37
Nivolumab
37
Letrozole
36
130-nm albumin-bound paclitaxel
32
Bortezomib
31
Prednisone
30
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 3
×
polatuzumab vedotin
×
90 days
×
Clear all
NCT03274492
2026-05-08
POLARIX
Hoffmann-La Roche
Phase 3
Completed
1,000 enrolled
1 FDA
NCT05171647
2026-05-07
SUNMO
Hoffmann-La Roche
Phase 3
Active not recruiting
208 enrolled
12 charts